Karyopharm Therapeutics Logo
US48576U2050
A40YLC

Karyopharm Therapeutics

Loading quotes...

Forecast

The analysts' average price target is €6.67 (+33,250.00%). The median is €2.73 (+13,550.00%).

Buy
  13
Hold
  6
Sell
  2

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, Karyopharm Therapeutics had revenue of €29.29M and net profit of -€58.73M
(EUR) June 2026
YoY
Revenue 29.29M 8.97%
Gross profit 28.34M 9.41%
Net profit -58.73M 85.81%
EBITDA -47.21M 114.80%

Fundamentals

Metric Value
Market capitalization
€371.41K
Number of shares
22.68M
52-week high/low
€10.00 - €0.00728
Dividends No
Beta
1.04
P/E ratio
0.00
PEG ratio
0.00
P/B ratio
0.00
P/S ratio
0.00

Company profile

Name
Karyopharm Therapeutics
CEO
Richard A. Paulson
Employees 228
🍪

Parqet  uses cookies. Learn more